Navigation Links
Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
Date:3/11/2008

- Cotara(R) Appears Safe and Well Tolerated in Dosimetry and Phase II

Trials, with Some Patients Already Past the Expected Median Average

Survival Time for This Population - - Data From Dosimetry Trial Accepted for Presentation at 2008 ASCO Annual

Meeting -

TUSTIN, Calif., March 11 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus infection, today released an update from two clinical trials assessing its targeted therapy Cotara(R) in the treatment of glioblastoma multiforme (GBM), the most deadly form of brain cancer. The Cotara clinical update covers the first cohort of patients in its dosimetry trial as well as experience to date in an ongoing Phase II safety and efficacy trial. In patients treated in the studies, Cotara appears to be safe and well tolerated, with no dose-limiting adverse events. Patients who are continuing in the trials are being monitored for safety and overall survival, with several surpassing the median expected survival time for relapsed GBM patients. The recent addition of new clinical sites in both the dosimetry and Phase II trials is expected to help accelerate the pace of patient enrollment going forward. The company also announced that data from the first patient cohort in the dosimetry trial has been accepted for presentation at the 2008 ASCO Annual Meeting.

"We are encouraged by early results from these two Cotara clinical studies and look forward to presenting data from the dosimetry trial at the upcoming ASCO Annual Meeting," said Steven W. King, president and CEO of Peregrine. "In v
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
2. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
3. Statement from American Water Works Association on Associated Press Story on Pharmaceuticals in Drinking Water
4. Vion Pharmaceuticals Regains NASDAQ Listing Compliance
5. NPS Pharmaceuticals to Report 2007 Financial Results
6. Trubion Pharmaceuticals Announces Dates for Fourth-Quarter and Year-End 2007 Earnings Conference Call
7. Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results
8. Notice of Bradmer Pharmaceuticals Conference Call
9. Transcept Pharmaceuticals to Present at Cowen and Companys 27th Annual Health Care Conference in Boston
10. ISTA Pharmaceuticals Announces Conference Call and Webcast of Fourth Quarter 2007 Financial Results
11. Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2014)... MD, April 22, 2014: The Association for Molecular ... The Journal of Molecular Diagnostics on recommendations ... baccalaureate and master,s levels of education. The report ... Curriculum Task Force of the AMP Training and ... critical need of educating future medical laboratory scientists ...
(Date:4/22/2014)... German . ... but their mode of action is complex: In low ... behavior, while at high concentrations they can cause "oxidative ... how redox signaling unfolds in single cells and organelles ... developed jointly by the teams of LMU Professor Martin ...
(Date:4/22/2014)... we all seem to know who we say is neurotic ... isn,t unable to act but simply doesn,t want to., ... study of nearly 4,000 college students in 19 countries has ... decisions and moving forward with life. Turns out that when ... just don,t like it as much as non-neurotics. Therefore persuasive ...
(Date:4/22/2014)... This news release is available in German . ... F. Perutz Laboratories of the University of Vienna and the ... Zurich, have now shown how double stranded RNA, such as ... a cell. During the immune response against viral infection, the ... cytoplasm. There it modifies viral RNA to inhibit reproduction of ...
(Date:4/22/2014)... like toddlers, but their total brain size suggests ... or fox squirrel, according to a new study ... from orangutans to zebra finches. , Scientists at ... than two-dozen other research institutions collaborated on this ... defined in the study as the ability to ...
Breaking Medicine News(10 mins):Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2Health News:Neuroimaging: Live from inside the cell 2Health News:Neurotics don't just avoid action: They dislike it 2Health News:How the body fights against viruses 2Health News:How the body fights against viruses 3Health News:Brain size matters when it comes to animal self-control 2Health News:Brain size matters when it comes to animal self-control 3
... MedCom USA, Inc.,(OTC Bulletin Board: EMED), a leading ... for the healthcare industry,has signed a distribution agreement ... force, the product line of MedCom USA.,MedCom,s products ... options which include Credit/Debit, Easy Pay and Check,Guarantee/EFT ...
... Heart Association says high blood sugar condition linked to ... -- A national effort is needed to deal with ... says an American Heart Association scientific statement released Monday. ... about the condition, also known as hyperglycemia, in people ...
... Rigel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced ... president of clinical research. In this newly,created position, ... and,oversight of Rigel,s clinical research programs in rheumatoid ... syk kinase,inhibitor, is expected to enter advanced Phase ...
... /Xinhua-PRNewswire-FirstCall/ -- Lotus,Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS; ... the United States that operates Beijing Liang,Fang Pharmaceutical ... Pharmaceutical,Co., Ltd. both of which are pharmaceutical companies ... that it has raised $5 million in,a private ...
... NEW YORK, Feb. 26 , WHO: New York Lt. Gov. David A. Paterson, along with stem ... R. Lyon, M.D., will be the keynote speakers at the 3rd ... p.m. on Tuesday, February 26 ... Trianon Ballroom 1335 Avenue ...
... BMR, TORONTO, Feb. 26 /PRNewswire-FirstCall/ ... dedicated to the development and,commercialization of ... II data,on the Company,s Neuradiab product ... glioblastoma multiforme (GBM) were published in ...
Cached Medicine News:Health News:MedCom USA Signs Southwood Medical Marketing to Distribute MedCom System 2Health News:MedCom USA Signs Southwood Medical Marketing to Distribute MedCom System 3Health News:MedCom USA Signs Southwood Medical Marketing to Distribute MedCom System 4Health News:National Effort Needed to Address Hyperglycemia in Heart Patients 2Health News:Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinical Research 2Health News:Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinical Research 3Health News:Lotus Pharmaceuticals Raises $5 Million in Private Placement 2Health News:Lotus Pharmaceuticals Raises $5 Million in Private Placement 3Health News:MEDIA ADVISORY: New York Lt. Gov. David Paterson and Stem Cell Experts to Participate in 3rd Annual Stem Cell Summit 2Health News:Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study 2Health News:Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study 3Health News:Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study 4
(Date:1/15/2014)... is very pleased to announce the appointment of Mr. ... Mark was promoted from his current role of Chief Operating ... in Massachusetts , Mississippi ... 2012 with 20+ years of broad-based operations, sales, engineering and ...
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... developing its Symphony® CGM System as a non-invasive, wireless ... F. Doman , Executive Chairman and Interim CEO of ... Markets, Tenth Annual Equity Conference. Mr. ...
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... Ga., May 3, 2011 Precyse , ... and technologies, announces the general availability of ... information management platform available today. PrecyseCode is driven ... voice, converting it to text and transforming it ...
... May 3, 2011 HistoRx, Inc., announced today ... researchers interested in using AQUA® technology.  HistoRx,s proprietary ... biomarkers, including measurement of protein concentration with sub-cellular ... microarrays.  These highly quantitative, standardized and reproducible results ...
Cached Medicine Technology:Precyse Announces Commercial Release of Revolutionary Intelligent Workflow Solution for Health Information Management 2Precyse Announces Commercial Release of Revolutionary Intelligent Workflow Solution for Health Information Management 3Precyse Announces Commercial Release of Revolutionary Intelligent Workflow Solution for Health Information Management 4Precyse Announces Commercial Release of Revolutionary Intelligent Workflow Solution for Health Information Management 5Precyse Announces Commercial Release of Revolutionary Intelligent Workflow Solution for Health Information Management 6HistoRx Announces Launch of New Research Services: AQUAPrep™ and Access AQUA® Services Now Available 2HistoRx Announces Launch of New Research Services: AQUAPrep™ and Access AQUA® Services Now Available 3
... The VersaPulse® PowerSuite™ holmium laser combines ... for precise, virtually bloodless procedures. It ... urinary and gall bladder stones of ... multipurpose surgical tool. Because its laser ...
... laser combines excellent cutting, ablation and ... procedures. It is also extremely effective ... stones of all compositions, making it ... its laser light is transmitted through ...
... adjustable height permits optimal leg position for the ... a cast with the foot/ankle at 90 degrees ... the tongue of the stand. Stockinette is pulled ... plaster/fiberglass is used in a routine fashion. The ...
... Techno-Aide provides the highest level of ... quality lead protective eyewear. Consistent ... tolerance allowed. Mfg supervised by Licensed ... lens meet or exceed standards for ...
Medicine Products: